Takeda Presents Results of Mobocertinib in P-I/II Study for Patients with EGFR Exon20 Insertion+ mNSCLC

 Takeda Presents Results of Mobocertinib in P-I/II Study for Patients with EGFR Exon20 Insertion+ mNSCLC

Takeda Presents Results of Mobocertinib in P-I/II Study for Patients with EGFR Exon20 Insertion+ mNSCLC

Shots:

  • The P-I/II study involves assessing Mobocertinib (160mg, PO) in patients with EGFR Exon20 insertion+ mNSCLC who received prior Pt-based CT
  • The results showed mobocertinib continued to demonstrate clinically meaningful benefit after over 1yr of follow up and will be presented at the ASCO. The updated results demonstrated an encouraging ORR (28%), DoR (17.5mos.), OS (24mos.), DCR (78%)
  • Mobocertinib has received the US FDA’s BTD in Apr’2020 and PR for NDA in Apr’2021. If approved, mobocertinib will be the first oral therapy available that is specifically designed to selectively target EGFR Exon20 insertion mutations

Click here to­ read full press release/ article | Ref: Takeda | Image: The Hindu Business Line

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post